Literature DB >> 7979305

Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital.

M C Layton1, J E Patterson.   

Abstract

Mupirocin resistance was determined in consecutive oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus clinical isolates collected over 14 months at a university hospital during 1991 and 1992. Twenty of 86 (23%) oxacillin-resistant and borderline oxacillin-resistant S. aureus isolates were mupirocin resistant; 80% were high-level resistant. Prior mupirocin use was a significant risk factor (relative risk, 6.08; 95% confidence interval, 3.7 to 9.99). Seven of 20 resistant isolates were distinct strains, as determined by pulsed-field gel electrophoresis typing. Two instances of clonal dissemination of a single strain occurred, but several other distinct mupirocin-resistant strains were documented. Mupirocin resistance was unexpectedly common among these isolates.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7979305      PMCID： PMC284613          DOI： 10.1128/AAC.38.7.1664

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

Review 2.  Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent.

Authors:  M W Casewell; R L Hill
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

3.  Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled trial.

Authors:  M W Casewell; R L Hill
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

4.  Nasal carriage of gentamicin and methicillin resistant Staphylococcus aureus treated with topical pseudomonic acid.

Authors:  J E Dacre; A M Emmerson; E A Jenner
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

5.  Transferable mupirocin-resistance.

Authors:  W C Noble; M Rahman; B Cookson; I Phillips
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

6.  Staphylococcus aureus resistant to mupirocin.

Authors:  G E Smith; C T Kennedy
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

7.  On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus.

Authors:  J Hughes; G Mellows
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

8.  An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir.

Authors:  M C Layton; M Perez; P Heald; J E Patterson
Journal:  Infect Control Hosp Epidemiol       Date:  1993-07       Impact factor: 3.254

9.  In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus.

Authors:  M W Casewell; R L Hill
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

10.  Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak.

Authors:  R L Hill; G J Duckworth; M W Casewell
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790
View more
  10 in total

1.  Clonal dissemination and mupA gene polymorphism of mupirocin-resistant Staphylococcus aureus isolates from long-term-care facilities in South Korea.

Authors:  Jae Il Yoo; Eun Shim Shin; Jeong Ok Cha; Jeom Kyu Lee; Young Hee Jung; Kyeong Min Lee; Bong Su Kim; Yeong Seon Lee
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In vitro activity of mupirocin against methicillin-resistant Staphylococcus aureus isolated from a hospital in Spain.

Authors:  T Alarcón; D Domingo; M C del Rey; S López; I Sánchez; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

3.  Bactericidal activity of tyrothricin against methicillin-resistant Staphylococcus aureus with reduced susceptibility to mupirocin.

Authors:  M Kretschmar; W Witte; H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

4.  Characterization of mupirocin-resistant Staphylococcus aureus from different geographic areas.

Authors:  M A Ramsey; S F Bradley; C A Kauffman; T M Morton; J E Patterson; D R Reagan
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 5.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus.

Authors:  S Harbarth; S Dharan; N Liassine; P Herrault; R Auckenthaler; D Pittet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates.

Authors:  M A Ramsey; S F Bradley; C A Kauffman; T M Morton
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Characterization of a conjugative staphylococcal mupirocin resistance plasmid.

Authors:  T M Morton; J L Johnston; J Patterson; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

9.  Staphylococcus aureus binding to human nasal mucin.

Authors:  J Shuter; V B Hatcher; F D Lowy
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains.

Authors:  T A Leski; M Gniadkowski; A Skoczyńska; E Stefaniuk; K Trzciński; W Hryniewicz
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.